A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)-Reference-Cited by-同舟云学术

A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)

Published:2023-05-28 Issue:4 Volume:12 Page:1221-1233
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Kim Hee-Jin^ORCID,Shim YongSoo,Han Hyun Jeong,Kim Byeong C.,Park Kee Hyung,Moon So Young,Choi Seong Hye,Yang Dong Won,Yoon Bora,Kim Eun-Joo,Jeong Jee Hyang,Han Seol-Heui

Funder

Lundbeck Korea

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00494-5.pdf

Reference30 articles.

1. Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s disease. J Alzheimers Dis. 2008;14(2):193–9.

2. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer’s disease: epidemiology and clinical progression. Neurol Ther. 2022;11(2):17.

3. Danysz W, Parsons CGJ. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18(S1):S23–32.

4. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699–723.

5. Winblad B, Poritis NJ. Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severly demented patients during treatment with memantine). Int J Geriat Psychiatry. 1999;14(2):135–46.